274 related articles for article (PubMed ID: 28569776)
1. HIV integrase inhibitor, Elvitegravir, impairs RAG functions and inhibits V(D)J recombination.
Nishana M; Nilavar NM; Kumari R; Pandey M; Raghavan SC
Cell Death Dis; 2017 Jun; 8(6):e2852. PubMed ID: 28569776
[TBL] [Abstract][Full Text] [Related]
2. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants.
Marinello J; Marchand C; Mott BT; Bain A; Thomas CJ; Pommier Y
Biochemistry; 2008 Sep; 47(36):9345-54. PubMed ID: 18702518
[TBL] [Abstract][Full Text] [Related]
3. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA
J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578
[TBL] [Abstract][Full Text] [Related]
4. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
Malet I; Subra F; Charpentier C; Collin G; Descamps D; Calvez V; Marcelin AG; Delelis O
mBio; 2017 Sep; 8(5):. PubMed ID: 28951475
[TBL] [Abstract][Full Text] [Related]
5. In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4.
Margot NA; Hluhanich RM; Jones GS; Andreatta KN; Tsiang M; McColl DJ; White KL; Miller MD
Antiviral Res; 2012 Feb; 93(2):288-296. PubMed ID: 22197635
[TBL] [Abstract][Full Text] [Related]
6. Structural Comparison of Diverse HIV-1 Subtypes using Molecular Modelling and Docking Analyses of Integrase Inhibitors.
Isaacs D; Mikasi SG; Obasa AE; Ikomey GM; Shityakov S; Cloete R; Jacobs GB
Viruses; 2020 Aug; 12(9):. PubMed ID: 32858802
[TBL] [Abstract][Full Text] [Related]
7. Second-generation integrase strand inhibitors can be effective against elvitegravir-derived multiple integrase gene substitutions.
Yotsumoto M; Hachiya A; Ichiki A; Amano K; Kinai E
AIDS; 2020 Nov; 34(14):2155-2157. PubMed ID: 32932342
[No Abstract] [Full Text] [Related]
8. Development of a phenotypic susceptibility assay for HIV-1 integrase inhibitors.
Heger E; Theis AA; Remmel K; Walter H; Pironti A; Knops E; Di Cristanziano V; Jensen B; Esser S; Kaiser R; Lübke N
J Virol Methods; 2016 Dec; 238():29-37. PubMed ID: 27737783
[TBL] [Abstract][Full Text] [Related]
9. Characterization and structural analysis of HIV-1 integrase conservation.
Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
[TBL] [Abstract][Full Text] [Related]
10. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143.
Métifiot M; Vandegraaff N; Maddali K; Naumova A; Zhang X; Rhodes D; Marchand C; Pommier Y
AIDS; 2011 Jun; 25(9):1175-8. PubMed ID: 21505303
[TBL] [Abstract][Full Text] [Related]
11. Examining structural analogs of elvitegravir as potential inhibitors of HIV-1 integrase.
Shah K; Gupta S; Mishra H; Sharma PK; Jayaswal A
Arch Virol; 2014 Aug; 159(8):2069-80. PubMed ID: 24643333
[TBL] [Abstract][Full Text] [Related]
12. HIV integrase inhibitors that inhibit strand transfer interact with RAG1 and hamper its activities.
Nilavar NM; Raghavan SC
Int Immunopharmacol; 2021 Jun; 95():107515. PubMed ID: 33735713
[TBL] [Abstract][Full Text] [Related]
13. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA
J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
[TBL] [Abstract][Full Text] [Related]
14. Biochemical activity of RAGs is impeded by Dolutegravir, an HIV integrase inhibitor.
Nilavar NM; Paranjape AM; Raghavan SC
Cell Death Discov; 2020; 6():50. PubMed ID: 32566255
[TBL] [Abstract][Full Text] [Related]
15. Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes.
Bar-Magen T; Sloan RD; Faltenbacher VH; Donahue DA; Kuhl BD; Oliveira M; Xu H; Wainberg MA
Retrovirology; 2009 Nov; 6():103. PubMed ID: 19906306
[TBL] [Abstract][Full Text] [Related]
16. In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir.
Canducci F; Ceresola ER; Saita D; Castagna A; Gianotti N; Underwood M; Burioni R; Lazzarin A; Clementi M
J Antimicrob Chemother; 2013 Nov; 68(11):2525-32. PubMed ID: 23798668
[TBL] [Abstract][Full Text] [Related]
17. New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors.
Malet I; Gimferrer Arriaga L; Artese A; Costa G; Parrotta L; Alcaro S; Delelis O; Tmeizeh A; Katlama C; Valantin MA; Ceccherini-Silberstein F; Calvez V; Marcelin AG
J Antimicrob Chemother; 2014 Aug; 69(8):2118-22. PubMed ID: 24710029
[TBL] [Abstract][Full Text] [Related]
18. Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome.
Abram ME; Ram RR; Margot NA; Barnes TL; White KL; Callebaut C; Miller MD
PLoS One; 2017; 12(2):e0172206. PubMed ID: 28212411
[TBL] [Abstract][Full Text] [Related]
19. Diketoacid inhibitors of HIV-1 integrase: from L-708,906 to raltegravir and beyond.
Beare KD; Coster MJ; Rutledge PJ
Curr Med Chem; 2012; 19(8):1177-92. PubMed ID: 22214459
[TBL] [Abstract][Full Text] [Related]
20. Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility.
Van Baelen K; Van Eygen V; Rondelez E; Stuyver LJ
AIDS; 2008 Sep; 22(14):1877-80. PubMed ID: 18753927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
